Tuesday, December 6, 2011

Side Effects Management

Side effects!  OOOOOOGIE!  Antiretrovirals are the greatest thing to happen in the HIV community since the epidemic hit; however, there some major drawbacks to this salvation medication.  This certainly doesn't mean that they are not worth taking but it is very important to know what one will be facing and whether it will be tolerable and manageable in the long run.

First of all, I found an interesting article about an RCT that suggests there is little difference in tolerability to HAART between older adults and younger adults.  http://www.biomedcentral.com/1471-2318/10/S1/L34

Two important points to consider, however, is that many of the side effects of these drugs are similar to those that are seen in many of the other drugs that older adults are required to be taking and the combination of these drugs with ARV can cause problems depending on how they are processed by the body (ie liver or kidneys).

The tables below from the University of California, San Francisco gives a WONDERFUL outline of current ARVs and their side effects along with comments.  http://hivinsite.ucsf.edu/insite?page=ar-05-01



Nucleoside Reverse Transcriptase Inhibitors
transparent image
  • NRTIs are associated with lactic acidosis, hepatic steatosis, and body fat redistribution (lipodystrophy).
DrugAdverse EventsComments
Abacavir
  • Hypersensitivity syndrome (fever, myalgia, malaise, nausea, vomiting, symptoms suggestive of upper respiratory tract infection, anorexia); symptoms progressively worsen with each subsequent dose; rash occurs in about half of cases
  • Rash
  • Headache, nausea, vomiting, diarrhea
  • Hypersensitivity reaction usually occurs in the first 6 weeks of treatment.
  • Hypersensitivity reaction may be more severe with once-daily abacavir dosing.
  • Risk of hypersensitivity related to certain genetic factors, particularly HLA B*5701; consider screening for this before prescribing abacavir.
  • Counsel patients on signs of hypersensitivity syndrome.
  • In case of hypersensitivity syndrome, abacavir must be discontinued permanently.
Didanosine
  • Pancreatitis
  • Peripheral neuropathy
  • Nausea, diarrhea
  • Concomitant alcohol use may increase risk of pancreatitis.
  • Lower frequency of diarrhea with enteric-coated capsules.
  • Increased risk of lactic acidosis and hepatic steatosis when combined with stavudine; this combination should be avoided when possible, especially during pregnancy.
  • Increased risk of peripheral neuropathy when combined with stavudine.
  • Adjust dosage for renal insufficiency or failure.
Emtricitabine
  • Headache, nausea, insomnia
  • Hyperpigmentation of palms and soles (occurs most frequently in dark-skinned people)
  • Active against hepatitis B virus (not approved by the U.S. Food and Drug Administration [FDA] for treatment of hepatitis B). In patients with HIV and hepatitis B coinfection, hepatitis may flare upon discontinuation of emtricitabine.
  • Adjust dosage for renal insufficiency or failure.
Lamivudine
  • Headache, dry mouth
  • Adverse effects occur infrequently.
  • Active against hepatitis B virus. In patients with HIV and hepatitis B coinfection, hepatitis may flare upon discontinuation of lamivudine.
  • Adjust dosage for renal insufficiency or failure.
Stavudine
  • Peripheral neuropathy
  • Pancreatitis
  • Dyslipidemia
  • Diarrhea
  • Of the NRTIs, stavudine appears to convey the greatest risk of lipodystrophy and other mitochondrial toxicity.
  • Increased risk of lactic acidosis and hepatic steatosis when combined with didanosine; this combination should be avoided when possible, especially during pregnancy.
  • Increased risk of peripheral neuropathy when combined with didanosine.
  • Consider dosage adjustment for peripheral neuropathy.
  • Adjust dosage for renal insufficiency or failure.
Tenofovir
  • Flatulence, nausea, diarrhea, abdominal discomfort
  • Asthenia
  • Acute renal insufficiency, Fanconi syndrome
  • Chronic renal insufficiency
  • Active against hepatitis B but not FDA approved for treatment of hepatitis B. In patients with HIV and hepatitis B coinfection, hepatitis may flare upon discontinuation of tenofovir.
  • Gastrointestinal symptoms may be worse in lactose-intolerant patients; tenofovir is formulated with lactose.
  • Adjust dosage for renal insufficiency or failure.
Zidovudine
  • Anemia, neutropenia
  • Fatigue, malaise, headache
  • Nausea, vomiting
  • Myalgia, myopathy
  • Hyperpigmentation of skin and nails
  • Twice-daily dosing preferred over thrice-daily dosing.
  • Fatigue, nausea, headache, and myalgia usually resolve 2-4 weeks after initiation.
  • Adjust dosage for renal insufficiency or failure.
transparent image
Nonnucleoside Reverse Transcriptase Inhibitors
transparent image
  • NNRTIs are associated with rash, and may cause Stevens-Johnson syndrome and toxic epidermal necrolysis.
  • All NNRTIs may have significant interactions with other drugs; dosage adjustment of interacting agents may be required.
DrugAdverse EventsComments
Delavirdine
  • Fatigue
  • Elevations in liver function tests, hepatitis
  • Nausea, diarrhea
  • 100 mg tablets can be dissolved in water.
  • Seldom used; less potent than other NNRTIs.
Efavirenz
  • Abnormal dreams, drowsiness, dizziness, confusion
  • Mood changes
  • Elevations in liver function tests
  • Hyperlipidemia
  • Central nervous system symptoms are common; severity usually decreases within 2-4 weeks.
  • Teratogenic in animal studies; contraindicated during the first trimester of pregnancy and for use by women who may become pregnant.
Etravirine
  • Elevations in liver function tests
  • Tablets may be dissolved in water.
  • Has significant interactions with many other drugs (may differ from those of first generation NNRTIs); screen carefully for drug interactions before prescribing.
  • Does not interact with methadone.
Nevirapine
  • Elevations in liver function tests, hepatitis, liver failure
  • Initial dose of 200 mg per day for first 14 days, then 200 mg twice daily (immediate-release formulation) or 400 mg once daily (extended-release formulation), decreases frequency of rash.
  • Most rash develops within first 6 weeks of therapy; rash is most common in women.
  • Hepatotoxicity may be life threatening. It is more common at higher CD4 cell counts, in women, and in patients with hepatitis B or C. Nevirapine should not be initiated for women with CD4 counts of >250 cells/µL or men with CD4 counts of >400 cells/µL, unless the benefit clearly outweighs the risk. Monitor liver tests closely for the first 16 weeks of treatment.
Rilpivirine
  • Insomnia
  • Depression
  • Elevations in liver function tests
  • Elevations in serum creatinine
  • May be less potent if baseline HIV RNA >100,000 copies/mL
  • Requires acidic gastric environment for adequate absorption:
    transparent image
    • Must be taken with food.
    • Contraindicated with proton pump inhibitors.
    • Other antacid medications and H2 blockers require specific timing if used by persons taking rilpivirine.
transparent image
Protease Inhibitors
transparent image
  • All PIs are associated with metabolic abnormalities including dyslipidemia, hyperglycemia, insulin resistance, and lipodystrophy. (Atazanavir is less likely to cause dyslipidemia.)
  • PIs may increase the risk of bleeding in hemophiliacs.
  • PIs may have significant interactions with other drugs; dosage adjustment of interacting agents may be required.
DrugAdverse EventsComments
Atazanavir
  • Hyperbilirubinemia, jaundice
  • Elevations in liver function tests
  • PR interval prolongation
  • Proton pump inhibitors interfere with atazanavir absorption and are contraindicated for use by patients receiving atazanavir.
  • Other antacid medications and H2 blockers also interfere with absorption of atazanavir and should be used with caution by patients receiving atazanavir.
  • Indirect hyperbilirubinemia; does not require discontinuation of atazanavir.
  • May have less effect than other PIs on lipid levels.
Darunavir
  • Rash
  • Elevations in liver function tests
  • Increases pravastatin (and other statin) levels; no significant interaction with atorvastatin.
Fosamprenavir
  • Diarrhea, nausea, vomiting
  • Elevations in liver function tests
  • Rash
  • Hyperlipidemia
  • Prodrug of amprenavir.
  • May cause rash in patients sensitive to or intolerant of sulfonamides.
Indinavir
  • Nephrolithiasis, flank pain
  • Hyperbilirubinemia
  • Elevations in liver function tests
  • Alopecia, dry skin, ingrown nails
  • Insomnia
  • Taste perversion
  • To reduce risk of nephrolithiasis, patients should drink at least 1.5 liters of fluid daily.
  • When used as sole PI, should be taken on an empty stomach, 1 hour before or 2 hours after a meal, and should be taken every 8 hours (not 3 times per day).
Lopinavir/ ritonavir
  • Diarrhea, nausea, vomiting
  • Dyslipidemia
  • Elevations in liver function tests
  • Taste perversion
  • Available in tablets or oral solution. Tablets do not require refrigeration.
  • Oral solution contains 42% alcohol.
  • Avoid combining oral solution with metronidazole or disulfiram. Alcohol in the oral solution may cause disulfiram-like reaction.
Nelfinavir
  • Diarrhea
  • Nausea, vomiting
  • Elevations in liver function tests
  • Fatigue
  • Diarrhea is very common. It usually can be managed with antidiarrheals such as loperamide and diphenoxylate/atropine.
Ritonavir
  • Nausea, vomiting, diarrhea, abdominal pain
  • Elevations in liver function tests
  • Fatigue
  • Circumoral or peripheral numbness
  • Taste perversion
  • Hyperuricemia
  • Capsules are stable at room temperature for up to 30 days.
  • Avoid combining oral solution with metronidazole or disulfiram. Alcohol in the oral solution may cause disulfiram-like reaction.
  • Has significant interactions with many other medications.
Saquinavir
  • Nausea, vomiting, diarrhea
  • Elevations in liver function tests
  • Headache
  • Oral ulcerations
  • Available in hard-gel capsules and tablets
  • Must be used in combination with low-dose ritonavir.
Tipranavir
  • Nausea, vomiting, diarrhea
  • Elevations in liver function tests
  • Increased total cholesterol and triglycerides
  • Rash
  • Intracranial hemorrhage
  • Must be coadministered with ritonavir; should never be used without ritonavir boosting.
  • Should be taken with food.
  • May cause rash in patients sensitive to or intolerant of sulfonamides.
  • Case reports of intracranial hemorrhage; association between tipranavir and intracranial hemorrhage is not clear.
  • Many drug-drug interactions. Certain drug combinations should be avoided. Consult current information before prescribing.
transparent image
Fusion Inhibitors
transparent image
DrugAdverse EventsComments
Enfuvirtide
  • Injection site reactions; erythema, cysts, and nodules at injection sites
  • Neutropenia
  • Possible increased frequency of pneumonia
  • Requires extensive patient counseling on injection technique, adherence, and management of possible side effects.
transparent image
Chemokine Coreceptor Antagonists
transparent image
DrugAdverse EventsComments
Maraviroc
  • Diarrhea, nausea
  • Elevations in liver function tests, hepatitis
  • Upper respiratory tract infections, cough
  • Fatigue, dizziness, headache
  • Joint pain, muscle pain
  • Many drug-drug interactions; dose adjustment needed with many other antiretrovirals and/or other medications. Consult current information before prescribing.
transparent image
Integrase Inhibitors
transparent image

DrugAdverse EventsComments
Raltegravir
  • Nausea, diarrhea, flatulence
  • Elevations in amylase and liver function tests
  • Headache
  • Dizziness, abnormal dreams
  • Pruritus, rash
  • Fatigue, muscle pain



These two YouTube links are to a PowerPoint lecture about ARV side-effect management

Part I
http://www.youtube.com/watch?v=7o0Xs7ffl6Y
Part II
http://www.youtube.com/watch?v=akncFuRRibQ&feature=related

Here are some more links to sites with some key information

http://www.avert.org/aids-drug-side-effects.htm

http://www.aidsbeacon.com/news/2010/08/24/side-effects-of-antiretroviral-treatment-hiv-and-bone-loss-aids-2010/


Wednesday, November 16, 2011

Treatment Issues


So treatment!  I'm not going to go into a lot of detail here about specific drug regimens since they would be the same as we would see among other age groups and vary greatly from practitioner to practitioner.  If you are interested in specific therapies and new innovations though, here is a great link to check out all the latest: http://www.hivatis.org/

What I would like to address here is some of the issues that are pertinent to older adults when it comes to treatment; what are the things that we need to be think about when we are treating our patients who are HIV positive and older?

The first thing that we need to take into consideration is drug interactions.  Antiretroviral therapies tend to have a lot of bad drug interactions.  In particular the protease inhibitors, which are a key part of most modern therapies, are metabolized in the liver and inhibits the metabolization of other drugs.  This increase the likelihood of  bad drug interactions.  Though this is, of course, as issue for all ages it becomes even more so for older adults because they tend to already be taking a great deal more medicines than younger folks because of any mixture of age related medical reasons.

And, speaking of these age-related illnesses; another problem we find with ART is that they tend to exacerbate these common ailments that we find in older adults.  Examples of this might include heart disease, high blood pressure, high cholesterol, diabetes, high triglyceride levels, kidney stones, inflammation of pancreas, liver damage, and bone loss which can lead to fracture.  In addition, it is common for older adults to already have a weakened immune system, which could make it difficult for them to respond to ART as a younger person might.

Another aspect that might also be considered is memory issues.  While some might suggest that we need to consider the fact that it may be more difficult for older adults to remember to take their ART, there are those who suggest that this population is already accustomed to taking several pills a day and adding a few more won't make that big a deal.  Thsi still needs to be on the table though simply because of the importance of adherance in ART.



There is still a LOT that needs to be understood about how these drug therapies work in older populations.  Most studies that have examined ART in the past have failed to include older adults as a population of concern.  These interactions and exacerbations will only continue to pose numerous challenges for both practitioners and patients alike until more attention given to this population.

http://www.bidmc.org/YourHealth/TherapeuticCenters/AIDS.aspx?ChunkID=14570

http://www.gmhc.org/files/editor/file/fall09.pdf

http://www.thebody.com/content/art14281.html

Tuesday, November 15, 2011

Prevention

Phew!  It's been awhile! :D  So this post is gonna look at issues of prevention that are specific to older adults.  The CDC has a great section on this exact topic so I just wanted to paraphrase some of the issue that come up with prevention in older adults here but I wanted to give you the link as well so you can explore a bit on your own: http://www.cdc.gov/hiv/topics/over50/resources/factsheets/over50.htm


As I have pointed out in earlier posts and whether we want to go there or not, your baby boomer parents are likely to be sexually active.  This can pose a problem when we think of HIV prevention because - well really - who's gonna get pregnant over the age of 50?  As such, older adults are rarely thinking of condom use when they become involved in an intimate relationship.  This becomes even more of an issue for women as they age because the lining of the vagina becomes much more fragile from dryness and thinning increasing the likelihood of tearing.  In addition to this, women face the reality (similar to that of younger women) of being in the sometimes uncomfortable position of having to negotiate condom use.



There is also the thought that older generations may be less informed about sexually transmitted infections such as HIV compared to that of younger folks partly because HIV was not a big part of their world when they were sexually active in their younger years and partly because they don't see themselves as being at risk.  This can lead to the misconception that condom use and regular testing for HIV is not something they need to worry about.  I, personally, would add here that the baby boomer generation has also been identified as a highly informed group when it comes to their health so it is important to take all of this into consideration.  Regardless, openly talking about sexual activity, regular testing for HIV, and promotion of condom use should be come a regular part of caring for older adults in primary care so we can break down the walls of stigma built up around sex in this population!



Which is a superb segue into issues of stigma as an obstacle to prevention.  While there are scattered articles about HIV related stigma we are a long way from knowing exactly how it affects older adults who are at risk for HIV.  Some believe there is little difference between older and younger populations and then there are those believe the exact opposite.  The CDC, for example, states that older adults may indeed be more highly affected by stigma robbing them of key emotional and spiritual support systems that might lead to early detection of HIV as well as prevention support.  On top of HIV related stigma it is prudent to be aware of other forms of stigma including age, race, as well as sexual and gender identity.  All of these can lead to decreased likelihood of seeking care and support from both family and the health care system.

This gives you a general idea of what we need to consider when we think of HIV prevention in older adults! I was very pleased to see amongst my browsing (some links will be posted below) to see that the general trend in prevention programs are now using a multifaceted approach in that, rather than simply telling a person to use condoms and get tested, the idea now is to use variations of prevention such as safer sexual practices, behavioral interventions, and medicinal considerations.

Anyway, here are some interesting sites to check out and browse!

http://www.thebody.com/content/64420/hiv-prevention-and-older-adults.html

http://www.med.unc.edu/aging/elderhiv/act.htm

http://www.med.unc.edu/aging/elderhiv/act.htm

http://aids.about.com/cs/aidsfactsheets/a/seniors.htm

http://caps.ucsf.edu/uploads/pubs/FS/over50.php

ENJOY!!  :D

Friday, October 28, 2011

Signs and Symptoms of HIV in Older Adults

So! what happens when one is infected with HIV?  Is it the same for everyone?  Hmmm . . .
Well, signs and symptoms of HIV in older adults can, in fact, be similar to that of younger adults in the early stages of infection.  However, when we add in common complications that occur with aging as well as a variety of chronic illnesses that can come with age, it’s not always so easy to distinguish between HIV and other problems.  Unfortunately, HIV is usually the last thing that is addressed in older adults or, in many cases, missed completely.

Many people have no symptoms when they first become infected with HIV. It can take as little as a few weeks for minor, flu-like symptoms to show up, or more than 10 years for more serious symptoms to appear. Signs of HIV can include headache, cough, diarrhea, swollen glands, lack of energy, loss of appetite, weight loss, fevers and sweats, repeated yeast infections, skin rashes, pelvic and abdominal cramps, sores in the mouth or on certain parts of the body, and short-term memory loss.  In the table below from Smith et al., you can see the frequency that one might see of the most common signs and symptoms.
Many HIV symptoms in older adults can resemble symptoms associated with a number of other illnesses that are commonly seen in the population.  Most commonly, these include fatigue, flu-like symptoms, respiratory problems, weight loss, chronic pain, night sweats, skin rashes, swollen lymph nodes, and neurological problems.
In addition, as the disease progresses, the effects of HIV may have a much greater impact on the aging adult.  According to Stoff et al. as found on the UNC website listed below, “Compelling evidence exists that natural history and symptom manifestations of HIV infection in the elderly substantially differ from those seen in younger cohorts. Relative to their younger counterparts, older adults living with HIV/AIDS have a more severe HIV disease course and a shorter survival rate; have less desirable health indices at diagnosis (e.g., lower CD4+ cell counts); have shorter AIDS-free intervals; have a higher number of opportunistic infections; and have earlier development of tumors and lesions.”

I think the take home message here is: while it may appear on the surface that everyone's response to HIV infection is the same, there may actually be much more we aren't seeing.  Of course, everyone is different and reacts differently but, with older adults, there can be many other things going on that can steer us away from HIV infection.  All in all:  remember to look outside the box! :D

Fitzpatrick, L. K. (2011). Routine HIV testing in older adults. American Medical Association Journal of Ethics, 13(2), 109-12. Retrieved from http://virtualmentor.ama-assn.org/2011/02/cprl1-1102.html

Smith, D. K., Grohskopf, L. A., Black, R. J., Auerbach, J. D., Veronese, F., Struble, K. A., Cheever, L., & Onorato, I. M. (2005, January 21). Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to hiv in the united states. Retrieved from http://www.thebody.com/content/art17171.html

The citation below is a great resource for medical matters!  They cover issues related to HIV in older adults in a variety of systems and disease states including the immune system, heart and blood vessels, high cholesterol and triglycerides, body weight, diabetes, the senses, the nervous system and mental health, bones, urinary system, liver, kidneys, skin, and cancer.

Ernst, J., Hufnagle, J., Karpiak, S., & Shippy, A. (2008). HIV and older adults. AIDS Community Research Initiative of America (ACRIA). [booklet]. Retrieved from http://www.acria.org/files/hiv-older-adults.pdf

Very cool website from the University of North Carolina.  The learning module walks you through aging and HIV; worth taking the time to work your way through. http://www.med.unc.edu/aging/elderhiv/welcome.htm

Saturday, October 22, 2011

Pathophysiology

So!  How does this thing - HIV - work?  Well, this is what it looks like! =)


Unfortunately folks, there is no real easy way to explain HIV so forgive me while I get a little technical for a bit here!

HIV is not the common type of virus most people have heard of, but rather, a lentivirus or a “slow” virus.  Like viruses, which must use the mechanisms of a cell to reproduce, HIV can’t act of its own accord – it too must have a host.  What distinguishes these retroviruses from other viruses is their mode of replication.  They use a combination of RNA and what is called a reverse transcriptase.  This genetic material is encased in a series of proteins that not only protect it, but allow it to dock and gain entry into its victims.


Two strands of RNA lie within what is called a capsid which is made up of about two thousand viral proteins called p24 and protects the delicate material until it is within the host cell and able to insert itself.  Next to these strands are the reverse transcriptases which will eventually allow the creation of a strand of DNA.  Two other proteins make up the interior of the virus: p7, which makes up the nucleocapsid and envelopes the strands of RNA; and p17, which makes up the matrix and borders the lipid membrane.  This viral core, as mentioned, houses this genetic strand, which is made up of nine genes.  Three of the genes – called gag, pol, and env – serve as the creators of the parts which will eventually make up new viruses.  The remaining six perform regulatory actions and are called tat, rev, nef, vif, vpr, and vpu.  These tend to deal with how the virus interacts with other cells and how the virus goes about replicating itself.


Surrounding the outer membrane of the virus is a series of proteins derived from a special protein made by the env gene called gp160.  This protein is broken into binding molecules of glycoproteins called gp120 and gp41.  These are what allow the virus to bind to receptors on the cd4 T-helper cells and eventually fuse with and penetrate the membrane.


So, in essence, what happens when the virus is introduced into the human body is that it is virtually served to its victim on a silver platter.  The most commonly known route of entry for HIV is transfer by sexual interactions whereby the virus enters the system through mucous membranes where it is picked up by macrophages and dendritic cells.  These escorts then proceed to the lymph nodes where they present their invaders to the cd4 T-helper cells allowing for the initial establishment of infection.


Once they have breached the system, they begin their hostile takeover.  The glycoprotein 120 receptors on the surface of the virus bind to specific receptors on the surface of the cd4 cells where they then begin the process of fusing with the cell’s membrane.  This is accomplished with the aid of the glycoprotein 41 unit which pierces the cells membrane allowing the two membranes to become one and introducing the capsid into the cell cytoplasm.  In the process the remaining gp120/gp41 complexes spread out across the surface of the new host cell.


This is where the reverse transcriptase comes into play.  Once inside, the capsid surrounding the viral RNA is dissolved and the p31 transcriptase is used to create an actual piece of DNA with all the complimentary encoding.  This string of DNA then forms a circle and enters the nucleus where it is inserted into the cell’s DNA, with the help of a protein enzyme called integrase, and is now termed a Provirus.  At this point, the virus can lie in wait for several years or it can proceed to duplicate itself with the help of its host.


There are two methods by which this new virus driven cell can take over other cells in its vicinity: budding and syncitium.   Budding can be quite devastating to the host cell.  To bud, the virus must replicate a new set of proteins to form new copies of its self.  This is accomplished with the help of its host using an RNA polymerase to create a messenger RNA, which is then moved out into the cytoplasm where it can be translated by a host ribosome into a variety of proteins.  This is one of the areas of production that cause HIV to be so tricky for researchers to get the best of this virus.  It seems that HIV tends to make a lot of slight errors when it replicates, pumping out hundreds of thousands of different variations of its self.  In other words, even if there isn’t a mix up in the translation there can certainly be a blending when they are put back together.


These proteins are reassembled to form the viral RNA and the capsid.  The outer membrane encompasses the new capsule, which then fuses with the outer membrane of the cell.  The receptor complexes merge with the rest of the membrane of the host and the new viral cell is ready to bud off and find a new host cell to take over.


The other method, by which the virus can usurp a neighboring cell, is by a process called syncitium.  In this case the infected cell literally absorbs what it comes in contact with.  When the viral host cell comes in contact with the new cell, their membranes fuse becoming one big cell.  All in all, this invader will overwhelm and virtually consume the entire immune system.

The pictures up above here are from the virtual patient reference library at the Carl J. Shapiro Institute of Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center.  The information gathered here came from my days in the BSN program; specifically from Pathophysiology: The biologic basis for disease in adults and children, 5th ed. by McCance and Huether.  Also from a particularly enlightening lecture in my Care in Illness class from a graduate student and now an HIV ARNP clinician name Karen Dykes.